Canada's Drug Agency Recommends Public Coverage for Alzheimer's Drug Donanemab

Canada's Drug Agency (CDA-AMC) has issued a positive draft recommendation supporting public reimbursement of donanemab (brand name Kisunla, Eli Lilly) for adults with mild cognitive impairment or mild dementia due to early-stage Alzheimer's disease. The recommendation, reported September 17 and updated September 18, 2026, reverses an earlier negative assessment of the drug and follows Health Canada's regulatory approval of donanemab on May 4, 2026 -- the second disease-modifying Alzheimer's therapy approved in Canada, after lecanemab. The decision is most relevant to specialty and hospital pharmacy teams involved in infusion therapy and to pharmacists fielding patient questions about a newly reimbursable option, rather than routine community dispensing.

Canada's Drug Expert Committee voted 11 to 3 in favour of the recommendation. Coverage would be limited to patients aged 50 and older with a confirmed diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease, and would exclude patients who are homozygous for the APOE4 gene variant, a group at higher risk of treatment-related brain swelling or bleeding. The committee also made the recommendation conditional on a significant price reduction from donanemab's current list price of roughly $47,250 per year before public drug plans would reimburse it.

"For people in the early stages of Alzheimer's disease and the care partners supporting them, maintaining autonomy and independence is profoundly important," said Christina Scicluna, CEO of the Alzheimer Society of Canada, in the organization's September 17 statement welcoming the recommendation. "Canada's Drug Agency's recommendation is a meaningful development, but health systems across the country will also need to take actions to prepare for the administration of new therapies. This includes ensuring that Canadians have access to a timely diagnosis, appropriate monitoring and practical supports so that eligible people and families can make informed decisions." The Society noted that accessing donanemab requires specialized capacity to confirm eligibility and monitor patients safely, including amyloid and genetic testing, intravenous infusion services, and MRI monitoring before and during treatment -- capacity it says varies significantly by region across Canada.

Practice guidance for pharmacists

• A draft recommendation is not final reimbursement -- actual coverage still depends on a final CDA-AMC recommendation, price negotiations through the pan-Canadian Pharmaceutical Alliance, and individual decisions by provincial and territorial drug plans, which can take significant additional time.
• Hospital and specialty pharmacists should confirm whether their institution has, or is building, the infrastructure this therapy requires: access to amyloid PET or CSF testing, APOE4 genetic testing, IV infusion capacity, and baseline plus on-treatment MRI monitoring for ARIA (amyloid-related imaging abnormalities).
• Community pharmacists are likely to field questions from patients and caregivers who saw this news and assume the drug is now covered or immediately available -- clarify that eligibility criteria (age 50+, non-APOE4-homozygous) and system readiness both still apply, and that a price reduction has not yet been finalized.
• Given the eligibility criteria depend on genetic and imaging testing most patients won't have already undergone, encourage early conversations with a memory clinic or specialist for patients who may want to pursue this option once (and if) it becomes reimbursed.

The recommendation is another step in what the Alzheimer Society of Canada calls Canada's "evolving Alzheimer's disease treatment landscape," following a similar reimbursement pathway for lecanemab earlier in 2026. The Society says continued investment in diagnostic and infusion capacity, not just the funding decision itself, will determine whether eligible Canadians can actually access the drug once province and territories finalize their own coverage decisions.